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Abstract
BACKGROUND: The European Prevention of Alzheimer’s 
Dementia (EPAD) Programme is a pan-European project whose 
objective is to deliver a platform, adaptive, Phase 2 proof of 
concept (PoC) trial for the secondary prevention of Alzheimer’s 
dementia. A component of this platform is the Longitudinal 
Cohort Study (LCS) which acts as a readiness cohort for the PoC 
Trial as well as generating data for disease modelling work in 
the preclinical and prodromal phases of Alzheimer’s dementia.
OBJECTIVES: The first data wave has been collected, quality 
checked, released and now available for analysis to answer 
numerous research questions. Here we describe the results from 
key variables in the EPAD LCS with the objective of using these 
results to compliment analyses of these data in the future.
DESIGN: EPAD LCS is a cohort study whose primary objective 
is as a readiness cohort for the EPAD PoC Trial. As such 
recruitment is not capped at any particular number but will 
continue to facilitate delivery of the EPAD PoC Trial. Research 
Participants are seen annually (with an additional 6 month visit 
in the first year).
SETTING: The EPAD Trial Delivery Network comprises 
currently 21 centres across Europe.
PARTICIPANTS: Research participants are included if they are 
over 50 years old and do not have a diagnosis of dementia. 
Measurements: All research participants undergo multiple 
assessments to fully characterise the biology of Alzheimer’s 
disease and relate this to risk factors (both fixed and 
modifiable) and biomarker expression of disease through 
brain imaging, fluid samples (CSF, blood, urine and saliva), 
cognitive performance, functional abilities and neuropsychiatric 
symptomatology.
RESULTS: V500.0 represents the first 500 research participants 
baselined into EPAD LCS. The mean age was 66.4 (SD=6.7) 
and 47.8% were male. The data was split for presentation into 4 
groups: [1] CDR=0 and Amyloid + (preclinical AD), [2] CDR=0 
and Amyloid –, [3] CDR=0.5 and Amyloid + (prodromal AD) 
and [4] CDR=0.5 and Amyloid -. 
CONCLUSIONS: The EPAD LCS is achieving its primary 
objective of trial readiness and the structured approach to data 
release as manifest by this first data release of V500.0 will assist 
researchers to describe and compare their findings as well as in 
systematic reviews and meta-analyses. It is anticipated given 
current recruitment rates that V1500.0 data release will take 
place in Autumn 2019. V500.1 (when the 1 year follow up is 
completed on the V500.0 (sub)cohort will be in Autumn 2019 
also.
Key words: EPAD, cohort, Alzheimer’s disease, prevention, disease 
modelling.
Background
The European Prevention of Alzheimer’s Dementia (EPAD) project was initiated in January 2015 and is funded by the Innovative 
Medicines Initiative. The overall project background 
and objectives are described elsewhere (1). In summary 
EPAD has a singular objective and that is to develop an 
entire infrastructure for the delivery of the EPAD Proof 
of Concept Trial. The EPAD PoC Trial is a platform trial, 
which employs a single master protocol with multiple 
appendices (representing each intervention) that uses 
Bayesian Adaptive Designs to develop interventions 
for the secondary prevention of Alzheimer’s dementia 
through Phase 2. The EPAD Infrastructure has many 
components including a virtual register of people in 
partnering parent cohorts across Europe, the Trial 
Delivery Centre (TDC) network, the PoC trial platform 
of TDCs, vendors and Clinical Research Organisations 
and the Longitudinal Cohort Study (LCS). The primary 
objective of the EPAD LCS is as a readiness cohort for 
the PoC to minimise screen failure by way of detailed 
characterisation of research participants within it and 
to provide run-in data to be used to compare with post-
randomisation data from the PoC itself. In accumulating 
vast amounts of data from a very large and highly 
characterised cohort, the EPAD LCS will be able to 
deliver data (eventually on an open data access platform) 
to the entire research community to assist with disease 
modelling and knowledge generation regarding the 
interplay between risk factors, brain disease, expression 
of brain disease (through biomarkers, cognition, function 
and neuropsychiatric symptoms) and how these change 
over time. Aware of the potential power of these data 
in the understanding of preclinical and prodromal 
Alzheimer’s disease, the management of data releases to 
the research community had to be measured, transparent 
and organised. Moreover, all data and sample collection 
and sample analysis has been conducted to the highest 
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GLP and GCP standards.              
The V500.0 data release represents the first formal 
data release from the EPAD project for use by multiple 
researchers. This paper describes this data in detail to 
assist current and future researchers with their analysis 
and also to facilitate between project comparisons of data 
in systematic reviews and meta-analysis.
Methods
The EPAD LCS Protocol and Methodology is provided 
in detail elsewhere (2). The EPAD LCS has as its primary 
objective to be a readiness cohort for the EPAD PoC Trial. 
Therefore, recruitment into LCS is not capped and will 
continue ad infinitum to provide the necessary number 
of suitable research participants for the EPAD PoC Trial. 
The secondary objective of the EPAD LCS is to use the 
data generated for disease modelling. After consent, 
research participants complete a comprehensive series of 
assessments. 
Research Participants are eligible for inclusion if they 
are over the age of 50 and do not have a diagnosis of 
dementia. They must also be deemed suitable in principal 
for later inclusion in a clinical trial and therefore should 
not have any medical or psychiatric disorders which 
would normally exclude people from such trials. 
Research Participants are seen every year where the 
entire protocol of assessments is completed. There is 
also a 6-month visit where only cognition is assessed. 
The domains of assessment are [1] cognition, [2] 
neuroimaging, [3] fluid biomarkers, [4] genetics, [5] 
lifestyle, [6] clinical and psychiatric assessment, [7] 
neuropsychiatric symptoms, [8] function and [9] basic 
demography. The decisions on which outcome measures 
to use were subject to intense deliberation and review 
of the extant scientific literature by four EPAD Scientific 
Advisory Groups on Cognition and Clinical Outcomes, 
Biomarkers, Neuroimaging and Genetics. 
Data releases from the EPAD LCS will be highly 
systematised. In our chosen nomenclature (V500.0): 
V=version, 500 is the number of sequentially recruited 
research participants and ‘.0’ refers to the data including 
only the baseline (visit 0) data. This subcohort will be 
followed over time so that the next release from this 
cohort V500.1 will take place in approximately 12 months. 
This will include all the baseline, 6 month and 12 month 
data from these 500 research participants. The ‘.1’ refers 
to the data including all data up until the 1 year visit, 
V500.2 will be when all data up until the 2 year visit is 
released.
Cognition and Clinical Outcomes
The Cognition and Clinical Scientific Advisory Group 
advised the LCS protocol authors on the construction 
of the EPAD Cognitive Examination (ECE) (3, 4) as 
well as on functional outcomes and the capturing of 
key neuropsychiatric features namely sleep, anxiety 
and depression. The cognitive outcomes captured are: 
RBANS (5, 6) (Primary Outcome Measure for EPAD 











Age (mean,SD) 66.4(6.7) 65.1(5.9) 65.9(6.5) 69.6(7.3) 71.9(6.5)
Gender
   Female 261(52.2%) 154(54.6%) 60(50.4%) 25(51%) 13(34.2%)
   Male 239(47.8%) 128(45.4%) 59(49.6%) 24(49%) 25(65.8%)
Marital Status
Married/cohabiting 377(75.4%) 221(78.4%) 89(74.8%) 34(69.4%) 27(71%)
 Divorced 55(11%) 24(8.5%) 15(12.7%) 9(18.4%) 6(15.8%)
 Single 36(7.2%) 19(6.7%) 6(5%) 4(8.2%) 3(7.9%)
 Widowed 32(6.4%) 18(6.4%) 9(7.6%) 2(4.0%) 2(5.3%)
Years of Education (mean,SD) 14.0(3.7) 14.2(3.6) 13.8(3.8) 13.7(3.8) 14.1(3.9)
Family History
(n,%)
 Yes 294(58.8%) 182(64.5%) 85(71.4%) 8(16.3%) 11(28.9%)
 No 206(41.2%) 100(35.5%) 34(28.6%) 41(83.7%) 27(71.1%)
ApoE4 Status (n,%)
   ApoEe4/- 286(57.2%) 99(35.1%) 59(49.6%) 10(20.4%) 21(55.3%)
   ApoEe4/4 191(38.2%) 172(61) 59(49.6%) 35(71.4%) 16(42.1%)
  Unknown 23 (4.6) 11(3.9%) 1(0.8%) 4(8.2%) 1(2.6%)
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PoC Trial), CDR (7), MMSE (8), NIH Toolbox tests 
(Dot Counting, Flanker) (9, 10), UCSF Brain Health 
Assessment (Favorites) (11), Supermarket Trolley Test 
(12) and Four Mountains Test (13). Function is assessed 
using the Amsterdam Instrumental Activity of Daily 
Living Assessment (14, 15). Sleep is assessed using the 
Pittsburgh Sleep Questionnaire (16); Anxiety is measured 
using the State/Trait Anxiety Inventory (17) and 
Depression using the Geriatric Depression Scale (18, 19). 
All cognitive and clinical data is captured on tablets 
(either on the Medavante Virgil Platform or the UCSF 
Tabcat System). These data are then uploaded to the 
EPAD LCS Master Database held by the EPAD LCS 
Clinical Research Organisation IQVIA for conciliation 
with other data sources e.g. imaging and eCRF data 
before being quality controlled and then pushed to the 
Analytical Database hosted by the EPAD Partner Aridhia.
Neuroimaging Outcomes
The Neuroimaging Scientific Advisory Group advised 
the LCS protocol authors on structural and functional 
MRI based evaluations optimised for understanding 
brain changes in preclinical and prodromal Alzheimer’s 
disease (20). The structural sequence captured in the 
protocol were Cortical thickness, deep grey matter 
volumes, fractional anisotropy of temporal lobe, diffusion 
kurtosis (multi b-valueDTI) and network alterations. The 
functional MRI outcomes were global & parietal CBF 
and changes within the default-mode network & relation 
with hippocampal activity(rsfMRI), Bolus arrival time 
(multi-delay arterial spin labelling) and network analysis 
(rsfMRI) though not all of these data have been analysed 
as yet in V500.0 and therefore not presented in this paper.
All brain-imaging facilities are accredited by the EPAD 
LCS Imaging CRO IXICO. Imaging files from the site 
are transferred to IXICO for central reading and safety 
evaluation. Key outcomes are then transferred to the 
Master Database for conciliation with other data feeds 
before these data are transferred to Aridhia and the 
EPAD Analytical Database. MRI scanners are a minimum 
of 1.5T.
Biomarker Outcomes
The Biomarker Scientific Advisory Group after review 
of the existing evidence around neuropathological 
changes in preclinical and prodromal AD had to 
decide which biomarkers were either fully validated as 
markers of disease or remained at the discovery phase of 
development. The former were to be incorporated in the 
protocol whilst the potential to explore the others would 
be reserved to a future date from EPAD LCS samples 
collected, shipped and stored under optimal conditions. 
The Biomarker SAG therefore also oversaw the creation 
of the laboratory manual (available on line at www.ep-ad.
org). 
The only biomarkers in the protocol are CSF ABeta, 
Tau and Phosphorylated Tau. All samples are shipped 
from sites and stored centrally at the EPAD BioBank 
at the University of Edinburgh before CSF samples 
taken in Sarstedt tubes are shipped to the University 
of Gothenburg, Sweden for analysis using the Roche 
Diagnostics Elecsys Platform. Results are then forwarded 
to the IQVIA Master Database and then transferred to 
the Aridhia Analytical Database. Using this system a 
threshold of 1,000pg/ml of ABeta42 was agreed upon to 
define amyloid positivity. 
Saliva (drooling sample and salivette), urine and 
plasma are also stored in the EPAD BioBank for future 
use. To date none of these samples have been analysed.
Genetics Outcomes
The Genetics Scientific Advisory Group had a similar 
remit to that of the Biomarker SAG in so much as they 
agreed on recommendations for outcomes to be done 












RBANS Total (mean/SD) 103.1(12.7) 104.7(12.0) 104.4(10.5) 100.1(14.7) 91.7(14.5)
RBANS DMI (mean/SD) 102.5(13.5) 103.7(11.5) 104.0(12.3) 102.9(14.9) 90.1(19.3)
RBANS List Learning 28.2(4.7) 28.6(4.4) 29.3(4.2) 26.9(4.6) 23.0(5.4)
RBANS Story Memory 18.2(3.1) 18.5(2.7) 18.7(2.9) 17.1(3.5) 15.8(4.4)
RBANS Figure Recall 14.2(3.9) 14.4(3.6) 15.0(3.3) 13.5(4.2) 10.6(4.8)
RBANS Figure Copy 18.6(1.9) 18.6(2.0) 18.6(1.6) 18.8(1.9) 18.2(1.8)
RBANS Line Orientation 18.0(2.2) 18.0(2.2) 18.4(1.8) 17.6(3.1) 17.6(2.1)
RBANS Picture Naming 9.8(0.9) 9.8(0.7) 9.9(0.4) 9.3(2.3) 9.8(0.6)
RBANS Semantic Fluency 19.2(5.6) 19.8(5.4) 19.4(5.5) 17.1(6.7) 16.6(5.0)
RBANS Digit Span 9.5(2.3) 9.6(2.3) 9.6(2.3) 9.2(1.9) 8.6(2.1)
RBANS Coding 43.9(10.8) 46.6(9.7) 43.6(9.1) 37.1(13.5) 34.0(10.6)
MMSE (Mean/SD) 28.6(1.6) 28.8(1.5) 28.8(1.3) 28.3(1.9) 27.6(1.7)
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optimal storage for future use. They recommended 
that all samples should be tested for ApoE status of the 
research participants. Sampling preparation and storage 
details can be found in the EPAD lab manual (available 
on line at www.ep-ad.org)
Taqman Genotyping was carried out in a single 
laboratory on QuantStudio12K Flex to establish ApoE 
variants. Genomic DNA was isolated from whole blood 
and genotyping was performed in 384 well-plates, using 
the TaqMan polymerase chain reaction-based method. 
The final volume PCR reaction was 5 μl using 20 ng 
of genomic DNA, 2.5 μl of Taqman Master Mix and 
0.125μl of 40x Assay By design Genotyping Assay Mix, 
or 0.25µl of 20x Assay On Demand Genotyping Assay. 
The cycling parameters were 95° for 10 minutes, followed 
by forty cycles of denaturation at 92° for 15 seconds and 
annealing/extension at 60° for 1 minute. PCR plates were 
then read on ThermoFisher QuantStudio 12K Flex Real 
Time PCR System instrument with QuantStudio 12K Flex 













0 338(67.6%) 209(74.1%) 83(69.8%) 27(55.1%) 17(44.7%)
1 119(23.8%) 61(21.7%) 31(26%) 9(18.4%) 17(44.7%)
2 21(4.2%) 8(2.8%) 4(3.4%) 6(12.2%) 2(5.4%)
3 7(1.4%) 0 1(0.8%) 5(10.2%) 1(2.6%)
4 0 0 0 0 0
Missing 15(3.0%) 4(1.4%) 0 2(4.1%) 1(2.6%)
Scheltens’ Score [Left]
0 347(69.4%) 223(79.1%) 78(65.5%) 30(61.2%) 14(36.8%)
1 113(22.6%) 48(17.0%) 39(32.8%) 8(16.3%) 17(44.8%)
2 19(3.8%) 7(2.5%) 2(1.7%) 5(10.2%) 4(10.5%)
3 5(1%) 0 0 3(6.2%) 2(5.3%)
4 1(0.2%) 0 0 1(2.0%) 0
Missing 15(3%) 4(1.4%) 0 2(4.1%) 1(2.6%)
Fazekas’ Score (Deep White Matter) 
0 129(25.8%) 83(29.4%) 29(24.4%) 10(20.4%) 6(15.8%)
1 267(53.4%) 149(52.9%) 65(54.6%) 32(65.3%) 19(50%)
2 78(15.6%) 44(15.6%) 17(14.3%) 5(10.2%) 11(29%)
3 11(2.2%) 2(0.7%) 8(6.7%) 0 1(2.6%)
Missing 15(3%) 4(1.4%) 0 2(4.0%) 1(2.6)
Fazekas’ Score (Periventricular White Matter)
0 273(54.6%) 168(59.6%) 62(52.1%) 28(57.1%) 12(31.6%)
1 136(27.2%) 72(25.5%) 40(33.6%) 13(26.6%) 11(29%)
2 67(13.4%) 35(12.4%) 14(11.8%) 5(10.2%) 12(31.6%)
3 9(1.8%) 3(1.1%) 3(2.5%) 1(2.0%) 2(5.2%)
Missing 15(3%) 4(1.4%) 0 2(4.1) 1(2.6%)
Hippocampal Volume R mm3 (Mean/SD) 2430.0(328.5) (n=480) 2449.2(293.0) (n=274) 2493.0(303.6) (n=118) 2370(308.2)  (n=47) 2208.9(496.9) (n=37)
Hippocampal Volume L mm3  (Mean/SD) 2354.6(318.0) 2385.0(282.4) 2395.0(295.5) 2267.5(295.0) 2139.2(493.4)








Whole Brain Volume mm3 (Mean/SD) 1103866 (108312.2) 1102517 (107156.7) 1118615 (108874.4) 1082654 (111207.5) 1093971 (107907.2) 
Ventricular Volume mm3 (Mean/SD) 27706.6 (16787.3) 24071.6 (13808.3) 30933.2 (18407.2) 29798.0 (16570.9) 40984.38 (22468.8)
Pseudo total intracranial volume factor 
(Mean/SD)
0.8386016 (0.0904448) 0.830509 (0.0904519) 0.8429424 (0.0906328) 0.8398999 (0.0867448) 0.8762338 (0.0892778) 
White Matter Lesion Volume mm3  
(Mean/SD)
17979.3 (41513.7) 12283.9 (33927.4) 32729.0 (54488.1) 8920.9 (20631.2) 25656.7 (53550.6) 
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Demographic, lifestyle, clinical and other 
outcomes
The EPAD LCS Protocol authors decided upon all 
outcomes following advice from the four listed Scientific 
Advisory Groups. Other outcomes were decided solely 
by the protocol authors. Lifestyle factors captured were 
self reported physical activity, diet, smoking/alcohol/
drug behaviour. Demography included gender, age, 
years of education and race (where allowable by regional 
authorities to be captured). Clinical history and physical 
examination was captured in standardised source 
documents to cover all medical and psychiatric domains 
including medication use. Specific assessment of head 
injury was undertaken using the Brain Injuries Screening 
Questionnaire.  
Results
All results are presented similarly as the total sample 
and by amyloid and CDR status. Some data on variables 
presented are missing and then within that grouping 
amyloid status may be missing too due to analysis 
problems. 
Lifestyle variables and medical history of research 
participants are not presented here but available on line 
on the EPAD website.
 
Discussion
The objective of this paper was to convey the structure 
of the EPAD LCS using the first data release from the 
project. With a large cohort that has open ended and 
perpetual recruitment, it was considered crucial that the 
academic and broader research community could have 
clarity on which data sets are being used from EPAD 
that form the basis of secondary data analysis. It is not in 
the scope of this paper to draw any conclusions from the 
data as no research question is being proposed here or 
hypothesis being tested. However, in terms of readiness 
for the EPAD PoC trial, just under 35% of the cohort are 
amyloid positive with the majority of these being CDR=0 
which probably reflects the initial source of recruitment 
to EPAD LCS from population based parent cohorts (21). 
To date 26.6% of the sample have preclinical Alzheimer’s 
disease and 8.3% prodromal Alzheimer’s disease. 
However with an increasing drive in recent months to 
significantly increase the proportion of people in the 
cohort with CDR=0.5 (in V500.0 = 14.8%) to nearer 30%, 
we expect confidently that by 2020 and commencement 
of the PoC trial, the LCS will have the necessary level 
of readiness. V500.0 also has a broad range of research 
participants in terms of many key outcomes that will 
assist in disease modelling work and other hypothesis 
testing. 
The quality of the data, sample preparation, storage 
and analysis was of paramount concern to the EPAD 
Consortium and much effort has gone into this with lab 
and imaging manuals available on the EPAD website 
to give researchers both assurance and clarity on the 
processes undertaken in EPAD to deliver high quality 
data.
The value of the EPAD LCS will clearly increase as the 
sample size increases and greater length of follow up is 
achieved in each sub-cohort. Description of each data 
release from EPAD is planned and will follow this initial 
formatting.
Conclusions
The EPAD Programme is a very large and ambitious 
programme that is ultimately set to deliver a platform, 
multi-arm PoC trial to test interventions targeting the 
secondary prevention of Alzheimer’s dementia. Whilst 











CSF ABeta 1330.5 (614.1) 1660.6 (490.2) 726.1 (194.2) 1701.8 (532.0) 678.3 (162.6)
CSF pTau 19.2(9.7) 18.2(8.0) 19.3(11.5) 18.8(6.3) 25.8(14.0)
CSF TTau 221.7(93.4) 216.8(82.8) 212.3(104.3) 228.0(71.3) 277.6(123.6)
CSF pTau/ABeta Ratio 0.018 (0.017) 0.0114 (0.005) 0.0293 (0.0197) 0.0117 (0.0046) 0.0422 (0.0313)
CSF TTau/ABeta Ratio 0.2118 (0.1699) 0.1358 (0.057) 0.3187 (0.1816) 0.1417 (0.0525) 0.4498 (0.2806)











Geriatric Depression Scale 4.88(4.7) (n=487) 4.26(4.4) (n=279) 4.68(4.9) (n=119) 6.5(4.7) (n=48) 7.9(4.7) (n=38)
State Trait Anxiety Inventory 64.5(15.7) (n=483) 62.4(14.5) (n=276) 64.8(16.3) (n=119) 68.4(14.9) (n=48) 73.0(16.0) (n=37)
Pittsburgh Sleep Quality Index 5.17(3.3) (n=485) 4.96(3.3) (n=278) 5.0(2.9) (n=117) 6.31(3.88) (n=48) 5.9(3.4) (n=38)
Amsterdam IADL 0.77(2.42) (n=480) 0.29(0.8) (n=273) 0.36(0.89) (n=118) 1.71(3.7) (n=45) 4.48(5.93) (n=38)
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the project has numerous key components, the EPAD 
LCS is central to all the efforts. Data from this cohort will 
be of great value to the research community so managed, 
orderly, structured and well described data releases are 
critical as a reflection of the importance of this database 
and the time and effort all our research participants have 
committed and made to help understand Alzheimer’s 
disease before dementia develops and in doing so move a 
step closer to its prevention.
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